Want to see AEON full AI Analyst Report?
AEON Biopharma (AEON) Ratios
AEON Biopharma Ratios
AEON's free cash flow for Q2 2026 was $-3.70M. For the 2026 fiscal year, AEON's free cash flow was increased by $0.00 and operating cash flow was $-3.70M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 |
| Quick Ratio | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 |
| Cash Ratio | 0.44 | 0.00 | 0.40 | 0.12 | 0.25 |
| Solvency Ratio | -0.65 | 1.33 | -2.40 | -0.19 | -0.24 |
| Operating Cash Flow Ratio | -2.51 | -1.43 | -3.67 | -0.43 | -1.37 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -0.50 | -1.82 |
| Net Current Asset Value | $ -57.19M | $ -30.12M | $ -153.67M | $ -271.35M | $ -225.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 6.43 | 4.12 | 0.04 | 12.20 | 13.50 |
| Debt-to-Equity Ratio | -0.65 | -0.45 | -0.00 | -0.46 | -0.37 |
| Debt-to-Capital Ratio | -1.85 | -0.83 | -0.00 | -0.84 | -0.59 |
| Long-Term Debt-to-Capital Ratio | -1.69 | -0.69 | 0.00 | -0.27 | -0.43 |
| Financial Leverage Ratio | -0.10 | -0.11 | -0.04 | -0.04 | -0.03 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -0.68 | -2.36 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 3.17 | 0.52 | 0.00 | 0.10 | 0.07 |
| Interest Debt Per Share | 3.60 | 22.53 | 0.00 | 68.22 | 49.57 |
| Net Debt to EBITDA | -2.02 | -0.47 | 0.09 | -2.52 | -2.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 306.35% | 57.55% | 110.50% | 108.52% | 84.49% |
| Return on Assets (ROA) | -705.43% | 1336.89% | -5619.17% | -487.62% | -864.47% |
| Return on Equity (ROE) | 71.28% | -147.03% | 251.32% | 18.28% | 23.68% |
| Return on Capital Employed (ROCE) | 957.59% | -663.08% | 5610.67% | 67.45% | 458.29% |
| Return on Invested Capital (ROIC) | 1180.00% | -670.45% | 5873.88% | 7195.99% | -5331.74% |
| Return on Tangible Assets | -705.43% | 1336.89% | -5619.17% | -487.62% | -864.47% |
| Earnings Yield | -359.38% | 187.89% | -0.96% | -4.12% | -4.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.74 | -35.29 | -0.62 | -18.46 | -16.22 |
| Free Cash Flow Per Share | -1.74 | -35.29 | -0.62 | -18.62 | -16.32 |
| Dividend Paid and CapEx Coverage Ratio | -4327.00 | 0.00 | 0.00 | -116.29 | -167.25 |
| Capital Expenditure Coverage Ratio | -4327.00 | 0.00 | 0.00 | -116.29 | -167.25 |
| Operating Cash Flow Coverage Ratio | -0.48 | -1.57 | -172.03 | -0.27 | -0.33 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -158.63% | -90.77% | -0.12% | -2.81% | -2.46% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.28 | 0.50 | -103.88 | -24.30 | -20.87 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.20 | -0.78 | -261.06 | -4.44 | -4.94 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.63 | -1.10 | -835.42 | -35.58 | -40.60 |
| Price-to-Operating Cash Flow Ratio | -0.63 | -1.10 | -835.42 | -35.89 | -40.84 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | 1.27 | 1.72 | 0.22 |
| Enterprise Value Multiple | -2.69 | -1.27 | -757.52 | -28.93 | -33.70 |
| Enterprise Value | 43.65M | 35.30M | 39.95B | 1.40B | 1.24B |
| EV to EBITDA | -2.69 | -1.27 | -757.52 | -28.93 | -33.70 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.52 | -1.74 | -835.32 | -38.98 | -43.46 |
| EV to Operating Cash Flow | -2.52 | -1.74 | -835.32 | -39.31 | -43.71 |
| Tangible Book Value Per Share | -5.55 | -49.69 | -1.99 | -140.26 | -127.68 |
| Shareholders’ Equity Per Share | -5.55 | -49.69 | -1.99 | -149.12 | -134.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.95 | 73.05 | -4.99 | -27.26 | -31.74 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.41 | -1.51 | 7.28 | 1.09 | 1.51 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.44 | -0.48 | 0.12 | 0.68 | 0.51 |
Currency in USD